←
Mereo BioPharma263 posts
Mereo BioPharma avatar

Mereo BioPharma

@MereoBioPharma

Mereo is a clinical-stage company focused on developing therapies in oncology & #orphandrugs / #rarediseasetherapies for #rarediseases

◷ Joined July 2017▧ 162 Photos and videos
Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·12 Dec 2022

As part of our mission to improve the lives of those with rare diseases, we are joining @rarediseasesint to call for Universal Healthcare Coverage for rare diseases. For the 300mil+ people with rare diseases, access to healthcare services is vital to their quality of life #UHCDay

Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·7 Dec 2022

The TIGIT Axis Therapies Digital Summit begins today, exploring the potential for next-generation TIGIT therapies. We are excited to hear from Suba Krishnan, SVP at Mereo, tomorrow @ 14.00 (EST) to share preliminary findings from Etigilimab + Nivolumab. https://t.co/MYY1f9ZCZk

Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·16 Nov 2022

Today is World #COPD Day, an opportunity for us all to support @GOLD_COPD’s “Your Lungs for Life" campaign. Testing for underlying genetic causes of COPD e.g. #AATD #Alpha1 can support understanding of contributing factors to COPD, improving lung health & protecting those at risk

Post attachment
Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·17 Oct 2022

We are pleased to announce the FDA has granted Fast Track designation for alvelestat for the treatment of AATD-LD, recognizing alvelestat as a potentially first-in-class oral neutrophil elastase inhibitor. We look forward to a R&D update on Oct 31 View PR: https://t.co/Ws0g8TXQzg

Post attachment
Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·12 Sep 2022

We are pleased to share updated clinical data for etigilimab + nivolumab in select recurrent advanced/metastatic solid tumors. View press release: https://t.co/mE9VF65QPB #TIGIT

Post attachment
Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·11 Sep 2022

A great session presenting biomarker analysis of etig + nivo from the ACTIVATE study at #ESMO2022. We are encouraged by the totality of biomarker data which may provide a roadmap for future clinical studies of etigilimab.

Post attachment
Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·9 Sep 2022

We are excited to share biomarker analysis of etigilimab + nivolumab in select recurrent advanced/metastatic solid tumors at the upcoming #ESMO2022. The poster will be available to view from 9am Central European Time, Sat 10 Sept.

Post attachment
Brittle Bone Society avatar
⟳ Mereo BioPharma retweeted
Brittle Bone Society@BrittleBoneUK·31 Aug 2022

We also had a talk from Dr Davina Ford and Dr Jennie Walsh who gave an overview of the Sheffield Transition process into Adult Services. Dr Ruth Kingshott also shared some resources on sleep, the BBS will update our website to include these. #oi2022

Post attachment
OI Foundation avatar
⟳ Mereo BioPharma retweeted
OI Foundation@OIFoundation·31 Aug 2022

OIF CEO Tracy Hart is currently attending the #OI2022 international OI meeting in Sheffield, UK! Yesterday, Tracy joined @BrittleBoneUK CEO Patricia Osborne and @OIFE_OI President Ingunn Westerheim on a panel to discuss the value and importance of patient engagement.

Post attachmentPost attachmentPost attachmentPost attachment
Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·17 May 2022

We are announcing the appointment of Dr. Abdul Mullick to our Board of Directors. His experience developing & commercializing rare disease products will be invaluable as we continue our journey to bring new treatments to those with rare diseases & cancer https://t.co/2H7nCVzbz5

Post attachment
Mereo BioPharma avatar
Mereo BioPharma@MereoBioPharma·9 May 2022

Mereo is pleased to report positive top-line Data from “ASTRAEUS” a Phase 2 trial of alvelestat in AATD. Join us at 10:30 ET for a conference call to discuss the data in more detail. See the press release for full dial-in details https://t.co/JaQVh47VAt @ScotsKnight2

Post attachment